Neuregulin-induced association of Sos Ras exchange protein with HER2(erbB2)/HER3(erbB3) receptor complexes in Schwann cells through a specific Grb2-HER2(erbB2) interaction.

Millennium Inc., Cambridge, Mass., USA.
Developmental Neuroscience (Impact Factor: 3.41). 02/2001; 23(1):25-30. DOI: 10.1159/000048693
Source: PubMed

ABSTRACT Neuregulins are members of the epidermal growth factor family of related ligands that exert pleotropic effects during development on the Schwann cell lineage. The receptor complex activated by neuregulin in Schwann cells consists of HER2 (erbB2) and HER3 (erbB3). The intracellular signaling events that follow activation of the HER2/HER3 receptor complex in primary cells, and in particular in Schwann cells, are poorly understood. We have found that neuregulin induces the rapid association of the guanine nucleotide exchange factor SOS with the HER2/HER3 receptor complex. The association of SOS with the HER2/HER3 receptor complex is preceded by the rapid association of Grb2 with the HER2/HER3 receptor complex. Far Western analysis indicates that Grb2 and SOS bind exclusively to HER2 in the HER2/HER3 receptor complex.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Neuregulins (NRG) play important roles in the development, maintenance, and repair of the nervous system, with influences on neuronal migration, synaptogenesis, receptor subunit composition, and the proliferation/survival of oligodendrocytes and Schwann cells. However, the precise detail of how the NRGs signal through ErbB receptors, particularly at central synapses, is incomplete. The receptor kinase domain provides sites for association with adaptor proteins. In addition, evidence from recent reports suggests that ErbB2/4 receptors, through their C-terminal amino acids, can form specific associations with scaffolding proteins. The existence of such assemblies expands the range of signaling cascades available to the NRGs.
    Molecular Neurobiology 03/2002; 25(1):67-77. · 5.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Schizophrenia is a devastating psychiatric disease, typically producing life-long disability. Initially considered a neurodegenerative disorder, schizophrenia is now viewed as a developmental disease due to the lack of neurodegenerative processes and because affected individuals exhibit cognitive and social impairment before the first psychotic episode (Lewis and Lieberman 2000). It has been proposed that schizophrenia may result from defects in early brain development that increase the risk of developing the disease as normal maturational events occur during adolescence or early adulthood. In addition, defects in late developmental events such as myelination or sexual maturation may also play a role. Genetic factors clearly account for a significant proportion of the underlying causes of schizophrenia.
    09/2007: pages 73-96;
  • [Show abstract] [Hide abstract]
    ABSTRACT: HER-2 proto-oncogene is important for oral carcinogenesis. HER-2 codon 655 polymorphism, either isoleucine (Ile: ATC) or valine (Val: GTC), was associated with the risk of breast carcinoma. This study investigated the clinicopathological implications of this polymorphism in oral carcinoma. We found that 79% of oral carcinoma patients had A/A (Ile/Ile) genotype and 21% had A/G (Ile/Val) genotype, with a G (Val) allelic frequency of 0.10. Univariate analysis indicated a significantly higher Val allelic frequency in cases having nodal metastasis or tumor recurrence; and Val allele was associated with poorer recurrence-free survival of patients. Multivariate analysis after adjusting confounding factors by logistic regression analysis indicated that patients carrying Val allele had a 8.79- and 4.25-fold higher risk for nodal metastasis and recurrence, respectively. Using Cox proportional hazard model, the risk of tumor recurrence was 3.35-fold higher in patients carrying Val allele. This is the first report demonstrating that the Val allele of HER-2 codon 655 could be an independent predictor for oral carcinoma progression.
    Oral Oncology 11/2008; 45(7):579-83. · 2.70 Impact Factor